Ginsenoside Rh2 Stereochemistry Inversion for Cancer Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer drugs derived from natural products face challenges such as poor solubility and cytotoxicity, particularly with the 20(R)-Rh2 isomer, which lacks cytotoxicity and exhibits poor intestinal absorption due to efflux mediated by ABC transporters, limiting their effectiveness against various cancer types.
Innovation Solution
A novel ginsenoside compound, chemically modified from 20(R)-Rh2, is synthesized through various methods involving catalysts like mono-persulfate, Zr(OtBu)4, Hf(OtBu)4, and VO(O-i-Pr)3, enhancing its cytotoxicity against cancer cells while maintaining non-toxicity to normal cells, and administered orally to treat a range of cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If 20(R)-Rh2 is used as the starting material, then the compound has poor solubility and is subject to efflux by ABC transporters, but it lacks cytotoxicity against cancer cells
Solution Approach 1:
The patent applies parameter changes by modifying the stereochemistry at C-24 from (R) to (S) configuration in the ginsenoside Rh2 molecule. This single stereocenter inversion transforms the compound from having poor solubility and efflux susceptibility to exhibiting enhanced cytotoxicity against cancer cells while maintaining adequate solubility properties
Solution Approach 2:
The invention exploits asymmetry by specifically inverting one stereocenter (C-24) while maintaining the (R) configuration at C-20. This selective asymmetric modification creates a diastereomer with dramatically different biological activity, converting a non-cytotoxic compound into a potent anti-cancer agent
2Object-affected harmful factors
If 20(S)-Rh2 is used, then the compound exhibits cytotoxicity against tumor cells, but it shows poor intestinal absorption due to efflux by ABC transporters
Solution Approach 1:
The patent modifies the molecular parameters by inverting the C-24 stereocenter configuration, which simultaneously improves cytotoxicity while addressing the absorption issue by creating a new stereoisomer with favorable pharmacokinetic properties
3Object-affected harmful factors
If chemical modification is performed to enhance cytotoxicity, then anti-cancer activity is improved, but the synthesis process becomes more complex
Solution Approach 1:
The invention applies local quality by making a highly targeted modification at a single specific location (C-24 stereocenter) in the molecule. This localized stereochemical inversion achieves the desired enhancement in anti-cancer activity without requiring complex global structural changes or multi-step synthesis procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compound demonstrates significant cytotoxicity against a panel of cancer cells with minimal impact on normal cells, showing potent suppressive effects on tumor growth and survival in animal models without adverse effects, indicating its potential as a novel chemotherapeutic agent.
Implementation Method 1
adding a catalyst solution to the mixture of step (b); standing the catalyzed mixture from step (c) for 8-24 hours at room temperature
Implementation Method 2
adding mono-persulfate compound and NaHCO3
Data Source
AI summary
The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.